- Addresses practical questions not covered in current guidelines
- Provides treatment recommendations based on hands-on clinical experience at major centres of excellence
- Aids the physician in prescribing for the hypertensive patient presenting with challenging conditions
- Specialists in hypertension and renal medicine
- General physicians
- Hospital pharmacists
1. What is endothelial cell dysfunction and does it impact capacity for vasodilatation?
P. P. Toth
2. Sleep disorders and hypertension
C. C. Gonzaga, D. A. Calhoun
3. Treatment of early morning surges in blood pressure
4. Use of out-of-office blood pressure monitoring versus office-based measurements for managing patients with hypertension
N. Ghuman, W. B. White
5. Is blood pressure control more important than decreasing activity in the renin-angiotensin axis?
W. J. Elliott
6. Is there a class effect for all angiotensin-converting enzyme inhibitors when evaluating end-organ protection?
P. P. Toth, D. Sica
7. Are angiotensin-receptor blockers equivalent or superior to ACE inhibitors relative to blood pressure control and/or end-organ protection?
R. R. Townsend
8. Treatment of hypertension in the post-stroke patient in both the acute and chronic setting
W. J. Elliott
9. Isolated systolic hypertension and management of hypertension in the very elderly
S. S. Franklin
10. Management of hypertension in patients with coronary artery disease
List of abbreviations
- DA Sica, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, Virginia, USA
- PP Toth, University of Illinois College of Medicine, Peoria, and Southern Illinois University School of Medicine, Springfield, Illinois, USA.